Postgenomic technologies targeting the Wnt signaling network

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 3, Issue 6, 2011, Pages 649-665

  Pancratov, Raluca ^a   Dasgupta, Ramanuj ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATENIN; WNT PROTEIN;

CHEMISTRY; DRUG ANTAGONISM; DRUG POTENTIATION; GENETICS; HUMAN; METABOLISM; MOLECULAR LIBRARY; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

CATENINS; HUMANS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; WNT PROTEINS;

EID: 80053535558     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.140     Document Type: Review

References (130)

1. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006, 127:469-480.
2. Nusse R. Wnt signaling in disease and in development. Cell Res 2005, 15:28-32.
3. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and β-catenin signalling: diseases and therapies. Nat Rev Genet 2004, 5:691-701.
4. Nusse R. WNT targets. Repression and activation. Trends Genet 1999, 15:1-3.
5. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998, 14: 59-88.
6. Yi F, Pereira L, Merrill BJ. Tcf3 functions as a steady-state limiter of transcriptional programs of mouse embryonic stem cell self-renewal. Stem Cells 2008, 26:1951-1960.
7. Katoh M. WNT signaling in stem cell biology and regenerative medicine. Curr Drug Targets 2008, 9:565-570.
8. Katoh M. Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev 2007, 3:30-38.
9. Neth P, Ries C, Karow M, Egea V, Ilmer M, Jochum M. The Wnt signal transduction pathway in stem cells and cancer cells: influence on cellular invasion. Stem Cell Rev 2007, 3:18-29.
10. Miller JR, Hocking AM, Brown JD, Moon RT. Mechanism and function of signal transduction by the Wnt/β-catenin and Wnt/Ca2+ pathways. Oncogene 1999, 18:7860-7872.
11. Semenov MV, Habas R, Macdonald BT, He X. SnapShot: noncanonical Wnt signaling pathways. Cell 2007, 131:1378.
12. Huber O, Korn R, McLaughlin J, Ohsugi M, Herrmann BG, Kemler R. Nuclear localization of β-catenin by interaction with transcription factor LEF-1. Mech Dev 1996, 59:3-10.
13. Hulsken J, Birchmeier W, Behrens J. E-cadherin and APC compete for the interaction with β-catenin and the cytoskeleton. J Cell Biol 1994, 127(6 Pt 2): 2061-2069.
14. Yanagawa S, Matsuda Y, Lee JS, Matsubayashi H, Sese S, Kadowaki T, Ishimoto A. Casein kinase I phosphorylates the Armadillo protein and induces its degradation in Drosophila. Embo J 2002, 21:1733-1742.
15. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3β and β-catenin and promotes GSK-3β-dependent phosphorylation of β-catenin. EMBO J 1998, 17:1371-1384.
16. Hamada F, Tomoyasu Y, Takatsu Y, Nakamura M, Nagai S, Suzuki A, Fujita F, Shibuya H, Toyoshima K, Ueno N, et al. Negative regulation of Wingless signaling by D-axin, a Drosophila homolog of axin. Science 1999, 283:1739-1742.
17. Willert K, Logan CY, Arora A, Fish M, Nusse R. A Drosophila Axin homolog, Daxin, inhibits Wnt signaling. Development 1999, 126:4165-4173.
18. Neufeld KL, Zhang F, Cullen BR, White RL. APC-mediated downregulation of β-catenin activity involves nuclear sequestration and nuclear export. EMBO Rep 2000, 1:519-523.
19. Henderson BR. Nuclear-cytoplasmic shuttling of APC regulates β-catenin subcellular localization and turnover. Nat Cell Biol 2000, 2:653-660.
20. Rosin-Arbesfeld R, Townsley F, Bienz M. The APC tumour suppressor has a nuclear export function. Nature 2000, 406:1009-1012.
21. Marikawa Y, Elinson RP. β-TrCP is a negative regulator of Wnt/β-catenin signaling pathway and dorsal axis formation in Xenopus embryos. Mech Dev 1998, 77:75-80.
22. Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, Durand H, Perret C, Rubinfeld B, Margottin F, Benarous R, et al. The F-box protein β-TrCP associates with phosphorylated β-catenin and regulates its activity in the cell. Curr Biol 1999, 9:207-210.
23. Liu C, Kato Y, Zhang Z, Do VM, Yankner BA, He X. β-Trcp couples β-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc Natl Acad Sci U S A 1999, 96:6273-6278.
24. Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, Harper JW. The SCFβ-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and β-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev 1999, 13:270-283.
25. Wu CH, Nusse R. Ligand receptor interactions in the Wnt signaling pathway in Drosophila. J Biol Chem 2002, 277:41762-41769.
26. Schweizer L, Varmus H. Wnt/Wingless signaling through β-catenin requires the function of both LRP/Arrow and frizzled classes of receptors. BMC Cell Biol 2003, 4:4.
27. Cliffe A, Hamada F, Bienz M. A role of Dishevelled in relocating Axin to the plasma membrane during wingless signaling. Curr Biol 2003, 13:960-966.
28. Lee E, Salic A, Kirschner MW. Physiological regulation of [β]-catenin stability by Tcf3 and CK1epsilon. J Cell Biol 2001, 154:983-993.
29. Farr GH 3rd, Ferkey DM, Yost C, Pierce SB, Weaver C, Kimelman D. Interaction among GSK-3, GBP, axin, and APC in Xenopus axis specification. J Cell Biol 2000, 148:691-702.
30. Li L, Yuan H, Weaver CD, Mao J, Farr GH 3rd, Sussman DJ, Jonkers J, Kimelman D, Wu D. Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J 1999, 18:4233-4240.
31. Yost C, Farr GH 3rd, Pierce SB, Ferkey DM, Chen MM, Kimelman D. GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell 1998, 93:1031-1041.
32. Tamai K, Zeng X, Liu C, Zhang X, Harada Y, Chang Z, He X. A mechanism for Wnt coreceptor activation. Mol Cell 2004, 13:149-156.
33. Mao J, Wang J, Liu B, Pan W, Farr GH 3rd, Flynn C, Yuan H, Takada S, Kimelman D, Li L, et al. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell 2001, 7:801-809.
34. Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, Okamura H, Woodgett J, He X. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 2005, 438:873-877.
35. Davidson G, Wu W, Shen J, Bilic J, Fenger U, Stannek P, Glinka A, Niehrs C. Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature 2005, 438:867-872.
36. MacDonald BT, Yokota C, Tamai K, Zeng X, He X. Wnt signal amplification via activity, cooperativity, and regulation of multiple intracellular PPPSP motifs in the Wnt co-receptor LRP6. J Biol Chem 2008, 283:16115-16123.
37. MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009, 17:9-26.
38. Staal FJ, Clevers H. Tcf/Lef transcription factors during T-cell development: unique and overlapping functions. Hematol J 2000, 1:3-6.
39. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004, 20:781-810.
40. Musgrove EA. Wnt signalling via the epidermal growth factor receptor: a role in breast cancer? Breast Cancer Res 2004, 6:65-68.
41. Nusse R. Wnts and Hedgehogs: lipid-modified proteins and similarities in signaling mechanisms at the cell surface. Development 2003, 130:5297-5305.
42. Lum L, Yao S, Mozer B, Rovescalli A, Von Kessler D, Nirenberg M, Beachy PA. Identification of Hedgehog pathway components by RNAi in Drosophila cultured cells. Science 2003, 299:2039-2045.
43. Behrens J. Cross-regulation of the Wnt signalling pathway: a role of MAP kinases. J Cell Sci 2000, 113(Pt 6):911-919.
44. Ishitani T, Kishida S, Hyodo-Miura J, Ueno N, Yasuda J, Waterman M, Shibuya H, Moon RT, Ninomiya-Tsuji J, Matsumoto K. The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/β-catenin signaling. Mol Cell Biol 2003, 23:131-139.
45. Ishitani T, Ninomiya-Tsuji J, Nagai S, Nishita M, Meneghini M, Barker N, Waterman M, Bowerman B, Clevers H, Shibuya H, et al. The TAK1-NLK-MAPK-related pathway antagonizes signalling between β-catenin and transcription factor TCF. Nature 1999, 399:798-802.
46. Meneghini MD, Ishitani T, Carter JC, Hisamoto N, Ninomiya-Tsuji J, Thorpe CJ, Hamill DR, Matsumoto K, Bowerman B. MAP kinase and Wnt pathways converge to downregulate an HMG-domain repressor in Caenorhabditis elegans. Nature 1999, 399:793-797.
47. Smit L, Baas A, Kuipers J, Korswagen H, van de Wetering M, Clevers H. Wnt activates the Tak1/ Nemo-like kinase pathway. J Biol Chem 2004, 279: 17232-17240.
48. Arsura M, Panta GR, Bilyeu JD, Cavin LG, Sovak MA, Oliver AA, Factor V, Heuchel R, Mercurio F, Thorgeirsson SS, et al. Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-β1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation. Oncogene 2003, 22:412-425.
49. Kaminska B, Wesolowska A, Danilkiewicz M. TGF β signalling and its role in tumour pathogenesis. Acta Biochim Pol 2005, 52:329-337.
50. Matsumoto-Ida M, Takimoto Y, Aoyama T, Akao M, Takeda T, Kita T. Activation of TGF-β1-TAK1-p38 MAPK pathway in spared cardiomyocytes is involved in left ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 2006, 290:H709-H715.
51. Hayward P, Brennan K, Sanders P, Balayo T, DasGupta R, Perrimon N, Martinez Arias A. Notch modulates Wnt signalling by associating with Armadillo/β-catenin and regulating its transcriptional activity. Development 2005, 132:1819-1830.
52. Helms W, Lee H, Ammerman M, Parks AL, Muskavitch MA, Yedvobnick B. Engineered truncations in the Drosophila mastermind protein disrupt Notch pathway function. Dev Biol 1999, 215:358-374.
53. Yedvobnick B, Helms W, Barrett B. Identification of chromosomal deficiencies that modify Drosophila mastermind mutant phenotypes. Genesis 2001, 30:250-258.
54. Alves-Guerra MC, Ronchini C, Capobianco AJ. Mastermind-like 1 is a specific coactivator of β-catenin transcription activation and is essential for colon carcinoma cell survival. Cancer Res 2007, 67:8690-8698.
55. Varelas X, Miller BW, Sopko R, Song S, Gregorieff A, Fellouse FA, Sakuma R, Pawson T, Hunziker W, McNeill H, et al. The Hippo pathway regulates Wnt/β-catenin signaling. Dev Cell 18:579-591.
56. He X. Unwinding a path to nuclear β-catenin. Cell 2006, 127:40-42.
57. Yang L, Lin C, Liu ZR. P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing axin from β-catenin. Cell 2006, 127:139-155.
58. Ciruna B, Jenny A, Lee D, Mlodzik M, Schier AF. Planar cell polarity signalling couples cell division and morphogenesis during neurulation. Nature 2006, 439:220-224.
59. Grove EA, Tole S, Limon J, Yip L, Ragsdale CW. The hem of the embryonic cerebral cortex is defined by the expression of multiple Wnt genes and is compromised in Gli3-deficient mice. Development 1998, 125:2315-2325.
60. Jiang R, Bush JO, Lidral AC. Development of the upper lip: morphogenetic and molecular mechanisms. Dev Dyn 2006, 235:1152-1166.
61. Kokubu C, Heinzmann U, Kokubu T, Sakai N, Kubota T, Kawai M, Wahl MB, Galceran J, Grosschedl R, Ozono K, et al. Skeletal defects in ringelschwanz mutant mice reveal that Lrp6 is required for proper somitogenesis and osteogenesis. Development 2004, 131:5469-5480.
62. Shu W, Jiang YQ, Lu MM, Morrisey EE. Wnt7b regulates mesenchymal proliferation and vascular development in the lung. Development 2002, 129:4831-4842.
63. Kaykas A, Yang-Snyder J, Heroux M, Shah KV, Bouvier M, Moon RT. Mutant Frizzled 4 associated with vitreoretinopathy traps wild-type Frizzled in the endoplasmic reticulum by oligomerization. Nat Cell Biol 2004, 6:52-58.
64. Robitaille J, MacDonald ML, Kaykas A, Sheldahl LC, Zeisler J, Dube MP, Zhang LH, Singaraja RR, Guernsey DL, Zheng B, et al. Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nat Genet 2002, 32:326-330.
65. Miyoshi K, Hennighausen L. B-catenin: a transforming actor on many stages. Breast Cancer Res 2003, 5:63-68.
66. Miyoshi K, Rosner A, Nozawa M, Byrd C, Morgan F, Landesman-Bollag E, Xu X, Seldin DC, Schmidt EV, Taketo MM, et al. Activation of different Wnt/β-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene 2002, 21:5548-5556.
67. Howe LR, Brown AM. Wnt signaling and breast cancer. Cancer Biol Ther 2004, 3:36-41.
68. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000, 24:245-250.
69. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000, 10:185-200.
70. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler B. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997, 275:1787-1790.
71. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275:1784-1787.
72. Moser AR, Luongo C, Gould KA, McNeley MK, Shoemaker AR, Dove WF. ApcMin: a mouse model for intestinal and mammary tumorigenesis. Eur J Cancer 1995, 31A:1061-1064.
73. Park JY, Park WS, Nam SW, Kim SY, Lee SH, Yoo NJ, Lee JY, Park CK. Mutations of β-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver Int 2005, 25:70-76.
74. Devereux TR, Stern MC, Flake GP, Yu MC, Zhang ZQ, London ZQ, Taylor JA. CTNNB1 mutations and β-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1. Mol Carcinog 2001, 31:68-73.
75. Chan EF. Pilomatricomas contain activating mutations in β-catenin. J Am Acad Dermatol 2000, 43: 701-702.
76. Chan EF, Gat U, McNiff JM, Fuchs E. A common human skin tumour is caused by activating mutations in β-catenin. Nat Genet 1999, 21:410-413.
77. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003, 1653:1-24.
78. Green DW, Roh H, Pippin JA, Drebin JA. B-catenin antisense treatment decreases β-catenin expression and tumor growth rate in colon carcinoma xenografts. J Surg Res 2001, 101:16-20.
79. Green DW, Roh H, Pippin JA, Drebin JA. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449:1003-1007.
80. Charafe-Jauffret E, Monville F, Ginestier C, Dontu G, Birnbaum D, Wicha MS. Cancer stem cells in breast: current opinion and future challenges. Pathobiology 2008, 75:75-84.
81. Chiba T, Zheng YW, Kita K, Yokosuka O, Saisho H, Onodera M, Miyoshi H, Nakano M, Zen Y, Nakanuma Y, et al. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 2007, 133:937-950.
82. Congdon KL, Voermans C, Ferguson EC, DiMascio LN, Uqoezwa M, Zhao C, Reya T. Activation of Wnt signaling in hematopoietic regeneration. Stem Cells 2008, 26:1202-1210.
83. Fodde R, Brabletz T. Wnt/β-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007, 19:150-158.
84. Kang S, Bennett CN, Gerin I, Rapp LA, Hankenson KD, Macdougald OA. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J Biol Chem 2007, 282:14515-14524.
85. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007, 23:675-699.
86. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, Weissman IL. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003, 423:409-414.
87. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006, 5:997-1014.
88. DasGupta R, Kaykas A, Moon RT, Perrimon N. Functional genomic analysis of the Wnt-wingless signaling pathway. Science 2005, 308:826-833.
89. Baeg GH, Zhou R, Perrimon N. Genome-wide RNAi analysis of JAK/STAT signaling components in Drosophila. Genes Dev 2005, 19:1861-1870.
90. Nybakken K, Vokes SA, Lin TY, McMahon AP, Perrimon N. A genome-wide RNA interference screen in Drosophila melanogaster cells for new components of the Hh signaling pathway. Nat Genet 2005, 37:1323-1332.
91. Friedman A, Perrimon N. A functional RNAi screen for regulators of receptor tyrosine kinase and ERK signalling. Nature 2006, 444:230-234.
92. Varelas X, Miller BW, Sopko R, Song S, Gregorieff A, Fellouse FA, Sakuma R, Pawson T, Hunziker W, McNeill H, et al. The Hippo pathway regulates Wnt/β-catenin signaling. Dev Cell 2010, 18:579-591.
93. Kennell JA, Gerin I, MacDougald OA, Cadigan KM. The microRNA miR-8 is a conserved negative regulator of Wnt signaling. Proc Natl Acad Sci U S A 2008, 105:15417-15422.
94. Kategaya LS, Changkakoty B, Biechele T, Conrad WH, Kaykas A, Dasgupta R, Moon RT. Bili inhibits Wnt/β-catenin signaling by regulating the recruitment of axin to LRP6. PLoS ONE 2009, 4:e6129.
95. Ma Y, Creanga A, Lum L, Beachy PA. Prevalence of off-target effects in Drosophila RNA interference screens. Nature 2006, 443:359-363.
96. DasGupta R, Nybakken K, Booker M, Mathey-Prevot B, Gonsalves F, Changkakoty F, Perrimon N. A case study of the reproducibility of transcriptional reporter cell-based RNAi screens in Drosophila. Genome Biol 2007, 8:R203.
97. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010, 9:57-67.
98. Major MB, Roberts BS, Berndt JD, Marine S, Anastas J, Chung N, Ferrer M, Yi X, Stoick-Cooper CL, von Haller PD, et al. New regulators of Wnt/β-catenin signaling revealed by integrative molecular screening. Sci Signal 2008, 1:ra12.
99. Cruciat CM, Ohkawara B, Acebron SP, Karaulanov E, Reinhard C, Ingelfinger D, Boutros M, Niehrs C. Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling. Science 2010, 327:459-463.
100. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, et al. CDK8 is a colorectal cancer oncogene that regulates β-catenin activity. Nature 2008, 455:547-551.
101. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, Piqani B, Eisenhaure TM, Luo B, Grenier JK, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006, 124:1283-1298.
102. Naik S, Dothager RS, Marasa J, Lewis CL, Piwnica-Worms D. Vascular endothelial growth factor receptor-1 is synthetic lethal to aberrant {β}-catenin activation in colon cancer. Clin Cancer Res 2009, 15: 7529-7537.
103. James RG, Biechele TL, Conrad WH, Camp ND, Fass DM, Major MB, Sommer K, Yi X, Roberts BS, Cleary MA, et al. Bruton's tyrosine kinase revealed as a negative regulator of Wnt-β-catenin signaling. Sci Signal 2009, 2:ra25.
104. Mosimann C, Hausmann G, Basler K. Parafibromin/ Hyrax activates Wnt/Wg target gene transcription by direct association with β-catenin/Armadillo. Cell 2006, 125:327-341.
105. Kikuchi A, Yamamoto H, Sato A. Selective activation mechanisms of Wnt signaling pathways. Trends Cell Biol 2009, 19:119-129.
106. Sierra J, Yoshida T, Joazeiro CA, Jones KA. The APC tumor suppressor counteracts β-catenin activation and H3K4 methylation at Wnt target genes. Genes Dev 2006, 20:586-600.
107. Kim S, Xu X, Hecht A, Boyer TG. Mediator is a transducer of Wnt/β-catenin signaling. J Biol Chem 2006, 281:14066-14075.
108. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW, Shivdasani RA. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell 2004, 5:91-102.
109. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, Moon RT, Teo JL, Kim HY, Moon SH, et al. A small molecule inhibitor of β-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A 2004, 101:12682-12687.
110. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009, 5:100-107.
111. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461:614-620.
112. Karner CM, Merkel CE, Dodge M, Ma Z, Lu J, Chen C, Lum C, Carroll TJ. Tankyrase is necessary for canonical Wnt signaling during kidney development. Dev Dyn 239:2014-2023.
113. Park S, Gwak J, Cho M, Song T, Won J, Kim DE, Shin JG, Oh S. Hexachlorophene inhibits Wnt/β-catenin pathway by promoting Siah-mediated β-catenin degradation. Mol Pharmacol 2006, 70:960-966.
114. Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neufeld KL, White RL, Matsunami N. Siah-1 mediates a novel β-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell 2001, 7:927-936.
115. Chen M, Wang J, Lu J, Bond MC, Ren XR, Lyerly HK, Barak LS, Chen W. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry 2009, 48:10267-10274.
116. Shan J, Shi DL, Wang J, Zheng J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 2005, 44:15495-15503.
117. Moore WJ, Kern JC, Bhat R, Commons TJ, Fukayama S, Goljer I, Krishnamurthy G, .Magolda RL, Nogle L, Pitts K, et al. Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides. J Med Chem 2009, 52:105-116.
118. Pelletier JC, Lundquist JTt, Gilbert AM, Alon N, Bex FJ, Bhat BM, Bursavich MG, Coleburn VE, Felix LA, Green DM, et al. (1-(4-(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine: a wingless β-catenin agonist that increases bone formation rate. J Med Chem 2009, 52:6962-6965.
119. Zhang Q, Major MB, Takanashi S, Camp ND, Nishiya N, Peters EC, Ginsberg MH, Jian X, Randazzo PA, Schultz PG, et al. Small-molecule synergist of the Wnt/β-catenin signaling pathway. Proc Natl Acad Sci U S A 2007, 104:7444-7448.
120. Collins MO, Choudhary JS. Mapping multiprotein complexes by affinity purification and mass spectrometry. Curr Opin Biotechnol 2008, 19:324-330.
121. Angers S, Thorpe CJ, Biechele TL, Goldenberg SJ, Zheng N, MacCoss MJ, Moon RT. The KLHL12-Cullin-3 ubiquitin ligase negatively regulates the Wnt-β-catenin pathway by targeting dishevelled for degradation. Nat Cell Biol 2006, 8:348-357.
122. Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, Maccoss MJ, et al. Wilms tumor suppressor WTX negatively regulates WNT/β-catenin signaling. Science 2007, 316:1043-1046.
123. Silver SJ, Hagen JW, Okamura K, Perrimon N, Lai EC. Functional screening identifies miR-315 as a potent activator of Wingless signaling. Proc Natl Acad Sci U S A 2007, 104:18151-18156.
124. Nagel R, le Sage C, Diosdado B, van der Waal M, Oude Vrielink JA, Bolijn A, Meijer GA, Agami R. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res 2008, 68:5795-5802.
125. Ying Y, Tao Q. Epigenetic disruption of the WNT/β-catenin signaling pathway in human cancers. Epigenetics 2009, 4:307-312.
126. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004, 36:417-422.
127. Jiang X, Tan J, Li J, Kivimae S, Yang X, Zhuang L, Lee PL, Chan MT, Stanton LW, Liu ET, et al. DACT3 is an epigenetic regulator of Wnt/β-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 2008, 13:529-541.
128. Castoreno AB, Smurnyy Y, Torres AD, Vokes MS, Jones TR, Carpenter AE, Eggert US. Small molecules discovered in a pathway screen target the Rho pathway in cytokinesis. Nat Chem Biol 6:457-463.
129. Perrimon N, Friedman A, Mathey-Prevot B, Eggert US. Drug-target identification in Drosophila cells: combining high-throughout RNAi and small-molecule screens. Drug Discov Today 2007, 12:28-33.
130. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004, 10:789-799.